Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Cytokinetics (CYTK) EBITDA Margin (2016 - 2025)

Cytokinetics (CYTK) has disclosed EBITDA Margin for 16 consecutive years, with 407.68% as the latest value for Q4 2025.

  • Quarterly EBITDA Margin changed N/A to 407.68% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 610.36% through Dec 2025, changed N/A year-over-year, with the annual reading at 893.61% for FY2025, 245091.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 407.68% at Cytokinetics, up from 15805.06% in the prior quarter.
  • The five-year high for EBITDA Margin was 23.29% in Q2 2022, with the low at 57751.41% in Q2 2024.
  • Average EBITDA Margin over 5 years is 11522.05%, with a median of 6919.32% recorded in 2022.
  • The sharpest move saw EBITDA Margin tumbled -4293595bps in 2024, then soared 5754761bps in 2025.
  • Over 5 years, EBITDA Margin stood at 78.29% in 2021, then tumbled by -8738bps to 6919.32% in 2022, then decreased by -18bps to 8135.89% in 2023, then plummeted by -309bps to 33290.71% in 2024, then soared by 99bps to 407.68% in 2025.
  • According to Business Quant data, EBITDA Margin over the past three periods came in at 407.68%, 15805.06%, and 203.8% for Q4 2025, Q3 2025, and Q2 2025 respectively.